Austria Cannot Offer Short Timelines For Reviewing Clinical Trials Under CTIS
Austria may not be part of an important monkeypox clinical trial taking place in several European Economic Area countries, but discussions on the study made the Austrian regulator realize its limitations in undertaking fast-track evaluations under the EU Clinical Trial Regulation.
You may also be interested in...
A full appraisal by the UK cost watchdog is not the only way to gauge the safety and effectiveness of Evusheld, argues the independent Drug Safety Research Unit in response to the government’s decision not to buy the licensed COVID-19 drug because of insufficient data on protection.
EU regulators have developed a draft good practice guide explaining how stakeholders can make use of the Metadata Catalog of RWD Sources, which is expected to be released in late 2023, to identify appropriate sources for specific research questions.
An updated Q&A on the EU Clinical Trial Regulation distinguishes between patient-facing documents and recruitment material to clarify in which sections of the trial application these should be submitted. It also underlines the main principles to consider for transitioning studies from the Clinical Trials Directive to the CTR.